<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<title>NCT04284787 – BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy</title>
<link rel="stylesheet" href="../assets/styles.css"/>
</head><body><div class="container">
  <a href="../index.html">← Back to index</a>
  <h1>NCT04284787</h1>

  <div class="card">
    <div><strong>Title:</strong> BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy</div>
    <div class="meta"><strong>Year:</strong>  &nbsp; <strong>Authors:</strong> —</div>
    <div class="meta"><a href="https://clinicaltrials.gov/study/NCT04284787" target="_blank" rel="noopener">Registry page</a></div>
  </div>

  <div class="card">
    <h3>Study Documents</h3>
    <ul class="list">
      <li>📄 <a href="https://cdn.clinicaltrials.gov/large-docs/87/NCT04284787/Prot_SAP_000.pdf" target="_blank" rel="noopener">Study Protocol and Statistical Analysis Plan</a></li>
<li>📄 <a href="https://cdn.clinicaltrials.gov/large-docs/87/NCT04284787/ICF_001.pdf" target="_blank" rel="noopener">Informed Consent Form</a></li>
    </ul>
  </div>

  <div class="card">
    <h3>Preview</h3>
    <iframe class="pdf-iframe" src="https://mozilla.github.io/pdf.js/web/viewer.html?file=https://cdn.clinicaltrials.gov/large-docs/87/NCT04284787/Prot_SAP_000.pdf"></iframe>
  </div>
</div></body></html>
